GlassScriptPhysician profile
Joanna Lopez
NPI 1871889345
$669,664.09
in general payments reported to CMS, 2019-2025
34 companies · $235K in 2025
The $235K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,505 · 2020: $17K · 2021: $37K · 2022: $103K · 2023: $91K · 2024: $179K · 2025: $235K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $409K · Travel and Lodging: $58K · Consulting Fee: $27K · Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $408,662.86 |
| Travel and Lodging | $57,776.86 |
| Consulting Fee | $27,390.00 |
| Food and Beverage | $10,431.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $225,204.90 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $202,029.78 | 2019-2025 | Tremfya, Stelara |
| Abbvie INC. | $135,914.16 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $55,130.32 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $35,765.80 | 2021-2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $4,650.00 | 2023 | Rebyota |
| Pfizer INC. | $4,110.35 | 2019-2025 | |
| Amgen INC. | $2,445.04 | 2020-2023 | Amjevita |
| Pharmacosmos Therapeutics INC. | $1,500.00 | 2021 | |
| Celgene Corporation | $991.64 | 2021-2024 | Zeposia |
| Celltrion USA INC. | $666.15 | 2024 | Zymfentra, Vegzelma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.84 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $117.00 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $115.18 | 2019-2022 | |
| Pentax of America, INC. | $111.83 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $108.94 | 2022-2025 | |
| Redhill Biopharma INC. | $92.30 | 2021-2024 | Aemcolo, Talicia |
| Intercept Pharmaceuticals, INC. | $91.41 | 2019-2024 | Ocaliva |
| Lilly USA, LLC | $64.90 | 2023-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $46.38 | 2024-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $43.39 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $38.05 | 2022-2023 | Dupixent |
| Allergan, INC. | $37.57 | 2020 | |
| Madrigal Pharmaceuticals | $32.69 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $30.83 | 2024 | Iqirvo |
| Ethicon US, LLC | $24.07 | 2019 | |
| Evoke Pharma, INC. | $20.43 | 2024 | |
| Concordia Pharmaceuticals INC. | $19.13 | 2019 | |
| Shire North American Group INC | $18.73 | 2019 | |
| Vivus LLC | $17.54 | 2024 | Pancreaze |
| Shionogi INC | $16.91 | 2019 | |
| Braintree Laboratories, INC. | $16.50 | 2019 | |
| Endo Pharmaceuticals INC. | $14.39 | 2020 | |
| Ardelyx, INC. | $13.94 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.